Pharmaceuticals News and Research

RSS

Takeda's $2.37 billion settlement over Actos didn't attract enough claimants to participate in the deal

MT Services LLC, a Lawsuit Settlement News Reporting Company which operates lawsuitsettlementnews.com, announced today that Takeda Pharmaceutical Co.'s $2.37 billion settlement didn't attract enough claimants to participate in the deal, which said the company would fund the deal after 95% of claimants joined it.

18 Aug 2015

Hi-Tech acquires LG Sciences brand of Sports Nutrition and Bodybuilding products

Hi-Tech Pharmaceuticals, a leading global provider of Sports Nutrition, Weight loss products, and Contract Manufacturing services, and LG Sciences, one of the premier Sports Nutrition and Bodybuilding brands in the United States, today announced that Hi-Tech has acquired LG Sciences brand of Sports Nutrition products and Bodybuilding products.

18 Aug 2015

FSU study reveals new method for treating diabetes

A new Florida State University study is changing how researchers look at diabetes research and the drugs used to treat the disease.

18 Aug 2015

VA study examines use of medicinal maggots to heal diabetic foot ulcers

Maggot, or larval, therapy has been around since ancient times as a way to heal wounds. Now, the method has gone high-tech--in some ways--and it's being tested in a rigorous clinical trial at the Malcom Randall Veterans Affairs (VA) Medical Center in Gainesville, Fla. Recruitment is now underway.

18 Aug 2015

DelMar obtains additional funding to support ongoing research project with lead product candidate VAL-083

DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced an increase in funding of up to CDN$287,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) to support an ongoing research project.

17 Aug 2015

Omeros plans to file patent infringement lawsuit against Par

Omeros Corporation today, in response to investor questions, announced that it plans to file a patent infringement lawsuit against Par Pharmaceutical, Inc. and its subsidiary, Par Sterile Products, LLC in response to the Abbreviated New Drug Application (ANDA) filed by Par seeking FDA approval to market a generic version of Omeros' commercial drug Omidria (phenylephrine and ketorolac injection) 1%/0.3%.

17 Aug 2015

FDA accepts Chiasma's NDA filing for octreotide capsules for treatment of adult patients with acromegaly

Chiasma, Inc., a U.S. late-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration has accepted for filing the Company's New Drug Application (NDA) for the marketing and sale of octreotide capsules, an oral drug proposed for the maintenance therapy of adult patients with acromegaly.

17 Aug 2015

New study examines how race and gender relate to Medicare Part D's coverage gap

Medicare Part D provides help to beneficiaries struggling with the cost of prescriptions drugs, but the plan's coverage gap hits some populations harder than others, particularly African-Americans age 65 and older. Reaching, or even approaching, the gap affects access to medication and influences whether those medications are taken as prescribed.

15 Aug 2015

Envarsus XR granted FDA orphan drug designation for prophylaxis of organ rejection in kidney transplant patients

Veloxis Pharmaceuticals A/S, today announced that Envarsus XR was granted Orphan Drug status by the U.S. Food and Drug Administration for prophylaxis of organ rejection in patients who convert from immediate-release tacrolimus. Envarsus XR received marketing authorization from the FDA on July 10, 2015.

14 Aug 2015

CASI reports financial results for second quarter 2015

CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, today reported financial results for the three and six months ended June 30, 2015.

14 Aug 2015

Opioids produced by yeast; revealing the potential for cheaper pain relief

Researchers at Stanford University have genetically engineered yeast so it produces hydrocodone, a semi-synthetic opioid analgesic used in the United States for relief of moderate to severe pain.

14 Aug 2015

China Pharma Holdings revenue decreases 7.4% to $5.7 million in Q2 2015

China Pharma Holdings, Inc., an NYSE MKT listed corporation with its fully-integrated specialty pharmaceuticals subsidiary based in China, today announced financial results for the quarter ended June 30, 2015.

14 Aug 2015

WuXi PharmaTech signs definitive and merger agreements

WuXi PharmaTech (Cayman) Inc., a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries with operations in China and the United States, today announced that it has entered into a definitive Agreement and Plan of Merger (the "Merger Agreement") with New WuXi Life Science Limited ("Parent") and WuXi Merger Limited ("Merger Sub"), a wholly owned subsidiary of Parent.

14 Aug 2015

CPhI reports positive outlook on the Chinese pharmaceutical market

CPhI – a division of UBM EMEA – alongside UBM Sinexpo, announces the findings of the Pharma Insights China 2015 report.

13 Aug 2015

RealTime Dynamix: New monthly service launched for pharmaceutical markets

Spherix Global Insights announces the launch of RealTime Dynamix, its new monthly service developed to keep clients on the pulse in highly dynamic specialty markets.

13 Aug 2015

Dipexium reports net loss of $4.0 million for second quarter 2015

Dipexium Pharmaceuticals, Inc., a late-stage pharmaceutical company focused on the development and commercialization of Locilex (pexiganan cream 0.8%), a novel, broad-spectrum, topical antibiotic peptide, today reported financial results for the quarter ended June 30, 2015.

13 Aug 2015

BDSI announces FDA approval of sNDA for new formulation of ONSOLIS (fentanyl buccal soluble film) CII

BioDelivery Sciences International, Inc. announced the approval by the U.S. Food and Drug Administration of a Supplemental New Drug Application (sNDA) for a new formulation of ONSOLIS (fentanyl buccal soluble film) CII for the management of breakthrough pain in patients with cancer who are opioid tolerant.

13 Aug 2015

Pharmaceuticals News and Research

Takeda's $2.37 billion settlement over Actos didn't attract enough claimants to participate in the deal

Hi-Tech acquires LG Sciences brand of Sports Nutrition and Bodybuilding products

FSU study reveals new method for treating diabetes

VA study examines use of medicinal maggots to heal diabetic foot ulcers

DelMar obtains additional funding to support ongoing research project with lead product candidate VAL-083

Omeros plans to file patent infringement lawsuit against Par

FDA accepts Chiasma's NDA filing for octreotide capsules for treatment of adult patients with acromegaly

New study examines how race and gender relate to Medicare Part D's coverage gap

Envarsus XR granted FDA orphan drug designation for prophylaxis of organ rejection in kidney transplant patients

CASI reports financial results for second quarter 2015

Opioids produced by yeast; revealing the potential for cheaper pain relief

China Pharma Holdings revenue decreases 7.4% to $5.7 million in Q2 2015

WuXi PharmaTech signs definitive and merger agreements

CPhI reports positive outlook on the Chinese pharmaceutical market

RealTime Dynamix: New monthly service launched for pharmaceutical markets

Dipexium reports net loss of $4.0 million for second quarter 2015

BDSI announces FDA approval of sNDA for new formulation of ONSOLIS (fentanyl buccal soluble film) CII

Food ingredient formulators use different ways to enhance absorption, bioavailability of curcumin, turmeric

FGF protein may play key role in breast and prostate cancer, shows research

CrystalGenomics signs agreement with Dong-A ST for commercialization of Acelex (polmacoxib) in Korea

Ultimate guide to the essential tools for the characterization of proteins, polymers and nanoparticles eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring